Combination of everolimus and tacrolimus: A potentially effective regimen for recalcitrant psoriasis

Dermatologic Therapy

Volumn 28, Issue 1, 2015, Pages 25-27

  Wei, Kai Che ^a   Lai, Ping Chin ^b,c  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

everolimus; mTOR inhibitor; psoriasis; tacrolimus

Indexed keywords

CORTICOSTEROID; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PREDNISOLONE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; ARTICLE; CASE REPORT; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG BLOOD LEVEL; FOLLOW UP; GOUT; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; MEDICAL HISTORY; MIDDLE AGED; PSORIASIS; ANALOGS AND DERIVATIVES; DRUG COMBINATION; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

DRUG THERAPY, COMBINATION; EVEROLIMUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 84920903885     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12176     Document Type: Article

References (14)

1. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007: 370: 263-271.
2. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009: 361: 496-509.
3. Nakajima K,. Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis. J Dermatol 2012: 39: 219-224.
4. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011: 306: 2331-2339.
5. Perrier C, Rutgeerts P,. Cytokine blockade in inflammatory bowel diseases. Immunotherapy 2011: 3: 1341-1352.
6. Igarashi A, Kato T, Kato M, et al. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012: 39: 242-252.
7. Foster RS, Bint LJ, Halbert AR,. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas J Dermatol 2012: 53: 52-56.
8. Paghdal KV, Schwartz RA,. Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol 2007: 57: 1046-1050.
9. Reitamo S, Spuls P, Sassolas B, et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001: 145: 438-445.
10. Ormerod AD, Shah SA, Copeland P, et al. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 2005: 152: 758-764.
11. Frigerio E, Colombo MD, Franchi C, et al. Severe psoriasis treated with a new macrolide: everolimus. Br J Dermatol 2007: 156: 372-374.
12. Jegasothy BV, Ackerman CD, Todo S, et al. Tacrolimus (FK 506)-a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992: 128: 781-785.
13. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002: 8: 128-135.
14. Young CN, Koepke JI, Terlecky LJ, et al. Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol 2008: 128: 2606-2614.